TPI obtains GMP certification for Qionglai Tianyin Facility

Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today announced that the TPI's Qionglai Tianyin Facility (QLF) has received its Good Manufacturing Practice (GMP) certificate from the China Food & Drug Administration's (CFDA) with the GMP certification processing number: SC20140067. The latest GMP certification has improved significantly regarding the level of stringency, standardization, quality control and etc and the receipt of the new GMP status is regarded a prominent advantage for the future growth of a pharmaceutical enterprise.

The GMP certification of QLF provides the basis for the growth platform of the strategic Alliance between TPI and Buchang Pharmaceutical Co., Ltd. ("Buchang Pharma", www.buchang.com and its Shanghai main board pre-IPO prospectus: http://www.csrc.gov.cn/pub/zjhpublic/G00306202/201406/t20140620_256436.htm) focusing on TPI's lead revenue driver Gingko Mihuan Oral Liquid (GMOL).

SOURCE Tianyin Pharmaceutical Co., Inc.